2 poumon 0- inopérable 1ère ligne 0 unresectable malignant pleural mesothelioma Nintedanib matching placebo Brest CHU (ICH)/

Transcription

1 ACRONYME Phase Organe X396-CLI-301 xalt 3 LungTech EORTC LUNGTE CH NéoAdj / Chir / Adj / M+ Ligne Statut génomique Cancer Shéma rapide Centres 0 > Alk + NSCLC ALK+ 0- inopérable 0 Inoperable Centrally Located NSCLC Experimental: X-396 (ensartinib) Active Comparator: crizotinib Experimental: Stereotactic Body Radiotherapy (SBRT) All eligible patients will be offered Stereotactic Body Radiotherapy using Fourdimensional computed tomography (4D- CT) planning (as a minimum), delivering a dose of 60 Gy in 8 fractions of 7.5 Gy on alternate days over a planned treatment time of 2.5 weeks Intervention: Radiation: Stereotactic Body Mesothelioma BIBF inopérable 0 unresectable malignant pleural mesothelioma Nintedanib matching placebo ACE-Lung IFCT IFCT1503ACE 0- inopérable non irradiable EGFR muté exon 19 deletion, L858R mutation, G719X, L861Q or S768I mutations or exon 19 insertion non-small cells lung cancer Afatinib Afatinib 40 mg/d until progression Intervention: Drug: Afatinib Experimental: Afatinib + cetuximab Afatinib 40 mg/d until progression + cetuximab 500 mg/m² every 2 weeks during 6 months (beginning at D15 at 250 mg/m²) Drug: Afatinib Drug: Cetuximab IFCT-1401 BR.31 BR31 IFCT1401 ACTRN MK KEYNOTE 091- PEARLS CA CheckMate 451 CheckMate adjuvant completelly resected non-small cells lung cancer 3-adjuvant 2eme ligne 4-maintenance maintenance complete surgical resection After Completion of Platinum-based First Line Chemotherapy UICC v7 Stage IB with T 4 cm, II-IIIA NSCLC at complete surgical resection with no residual disease (R0) after complete surgical resection (lobectomy/pneumonectomy) small cell lung cancer Drug: MEDI4736 Drug: Placebo Biological: pembrolizumab Other Name: MK-3475 Other: Placebo Biological: Nivolumab Biological: Ipilimumab Other: Placebo St Brieuc CH/ Rennes CHU/

2 GFPC advanced toutes lignes - CBNPC Stade III jugé non résécable radiothérapie + Chimiothérapie CA b, 4 poumon 5- advanced cancer avancé 0 Non small Cell Lung Cancer Experimental: Nivolumab in combination with Ipilimumab Intervention: Drug: Nivolumab in combination with Ipilimumab SPINET A-US Ascend-7 CLDK378A2205 CASPIAN D419QC MERU M orion - Atalante ATALANTE 1 - Ose OSE2101C301, advanced métastatic non rescable 5- advanced or métastatic 0 0 1ère, 2ème ou 3ème ligne 5- avancé, 5- extensive stage - advanced or metastatic 5- localement avancé (Unsuitable for Radiotherapy or Metastatic ) maintenance après une 1iere ligne de platine ALK+ Extensive Disease (Stage IV) 0 Tumeur neuroendocrine du poumon Bien différenciée, inopérable ou CBNPN + méta cérébrales SCLC extensive Disease (Stage IV) Small Cell Lung Cancer (SCLC) with ongoing clinical benefit (stable disease [SD], partial response [PR], or complete response [CR]) following completion of 4 cycles of first-line platinumbased therapy 2ieme, 3ieme Ligne HLA-A2 Positive cancer non à petites cellules Drug: Lanreotide (Autogel formulation) 120mg every 28 days until disease progression Other Names: Lanreotide Depot Somatuline Drug: Placebo Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression. Experimental: LDK378 LDK378 will be administered orally once daily at a dose of 750 mg (five 150 mg capsules) on a continuous dosing schedule. The treatment period will start on Cycle 1 Day 1. Intervention: Drug: LDK378 Experimental: Arm 1 durvalumab+tremelimumab+ep (carboplatin or cisplatin + etoposide) Experimental: Arm 2 durvalumab+ep (carboplatin or cisplatin + etoposide) Active Comparator: Arm 3 EP (carboplatin or cisplatin + etoposide) Experimental: Rovalpituzumab tesirine/dexamthasone Rovalpituzumab tesirine/dexamethasone every 6 weeks (q6 wk); omitting every third cycle Experimental: Placebo Placebo q6 wk; omitting every third cycle Drug: OSE2101 (Other Names: Tedopi, EP-2101, EP2101, IDM-2101) Drug: Docetaxel (Other Name:Taxotere) Drug: Pemetrexed (Other Name: Alimta)

3 ALTA-1L AP MM SHERLOC B localement avancé ou 5- locallement avancé ou 5- locallement avancé ou avancé ou < 3 lignes de traitement (primary or reccurrent) En echec après une ligne d'immunothérapie Mutation ALK positive Naïf de TKI Heregulin+, (ALK+) Mutation ALK positive NSCLC localement avancé ou NSCLC adenocarcinoma Squamous Cell Carcinoma Large celle carcinoma ALK-Positive NSCLC localement avancé ou Experimental: Brigatinib Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC naïve to ALK inhibitors at a dose of 90 mg QD for 7 days, then 180 mg QD, continuously, with or without food until disease progression, unacceptable toxicity, withdrawal of consent or death. Experimental: Arm A: Experimental Arm MM-121 in combination with either Docetaxel or Pemetrexed (Investigator's choice) Active Comparator: Arm B: Comparator Arm Docetaxel or Pemetrexed (Investigator's choice) alone Experimental: Lorlatinib Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously Active Comparator: Crizotinib Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously SPLENDOUR EORTC EGFR - ALK - CBNPC IV chimio vs chimio+denosumab 120 mg Brest CHU CH/ CINC280A ou localement avancé 2ème, 3ème ligne avancé ou EGFRALK- CBNPC IIIB/IV Oral cmet Inhibitor INC280 CA CA ou recidive suivant statut PDL1 et randomisation cancer non à petites cellules bras1: Nivolumab vs bras2: Nivolumab + Ipilimumab vs bras3: CT + Nivolumab vs bras4: CT TAHOE M ATLANTIS PM1183-C reccurent métastatic 6- reccurrent or métastatic 1ère rechute ou progression après la 1iere ligne de platine 2ieme ligne 2eme ligne (1iere progression après la 1iere ligne de platine) high levels of deltalike protein 3 (DLL3) Failed one prior platinum-containing regimen Small Cell Lung Cancer (SCLC) Small-Cell Lung Cancer (SCLC), CUP, with or without neuroendocrine features Experimental: Rovalpituzumab tesirine Rovalpituzumab tesirine intravenous administration on Day 1 of a 42-Day cycle for 2 cycles. Active Comparator: Topotecan Topotecan intravenous on Days 1 through 5 of each 21-Day cycle. Experimental: Test Lurbinectedin (PM01183) / Doxorubicin Drug: Lurbinectedin (PM01183) Drug: Doxorubicin (DOX) Active Comparator: Control 1 CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))

4 EMR JAVELIN-100 JAVELIN Lung recidive or PD1 PD-L1 positif PDL1 First Line Non-Small Cell Lung Cancer Drug: Avelumab Drug: Pemetrexed Drug: Paclitaxel Drug: Gemcitabine Drug: Carboplatin Drug: Cisplatin REFRACT I14041/REFRACT GFPC recidive / refractaire 2eme ligne refractory to first line no squamous non small cell lung cancer Drug: vargatef Drug: Docetaxel Brest CHU CH/St Brieuc CH/Quimper CH/ ATALK ML ieme ligne or recidive alk+ NSCLC Drug: Alectinib 600 mg orally BID with food CA LUNG ART IFCT Lung ART 0 early stage 0 Non small Cell Lung Cancer 3-adjuvant adjuvant - CBNPC Experimental: Nivolumab plus Ipilimumab Specified dose on specified days Biological: Nivolumab Biological: ipilimumab Active Comparator: Platinum doublet chemotherapy Specified dose on specified days Drug: cisplatin Drug: vinorelbine Drug: gemcitabine Drug: docetaxel Drug: pemetrexed Drug: carboplatin RT thoracique conformationnelle adjuvante vs pas de RT (TT adjuvant autorisé) Lorient CH/St Brieuc CARIO HPCA/St Brieuc CH/ STIMULI ETOP/IFCT 4-12 ETOP IFCT maintenance maintenance - CBPC I-IIIB ipilimumab après chimio-radiothérapie METAL 2 5- EGFR sauvage CBNPC IV non épidermoïde EGFR sauvage+ méta cérébrale asymptomatique à l'inclusion RT cérébrale + chimio vs chimio seule GFPC ème ligne - CBPC IV carboplatine vs topocetan Brest CHU CH/Quimper CH/ Brest CHU CH/St Brieuc CH/ M ou localement avancé localement avancé ou - CBNPC IIIB-IV non épidermoïde veliparib + carboplatin + paclitaxel vs placebo + carboplatin + paclitaxel

5 D5160C00036 AZD poumon - 2ième ligne EGFR mutation NSCLC Progression sous EGFR Tki de 1iere et 2ieme génération Experimental: osimertinib and fexofenadine Sequential treatments of fexofenadine alone followed by osimertinib + fexofenadine, followed by osimertinib alone, followed by osimertinib + fexofenadine I4X-MC-JFCU M DARZALEX CR b poumon 5- advanced métastatic toutes lignes - Non-Small Cell Lung Cancer (Stage IIV) 1 poumon 5- avancé 2ème ligne ou plus 1b, 5- avancé ou Progression après platine Carcinome pulmonaire à petites cellules (SCLC) disséminé > PDL1 + Non-Small-Cell Lung, advanced or metastatic Drug: Necitumumab Administered IV. Other Name: LY Drug: Abemaciclib Administered orally. Other Name: LY nivolumab Rovalpituzumab tesirine 0.3 mg/kg intravenous (various dose regimens) and nivolumab intravenous (various doses and dose regimens) nivolumab plus ipilimumab 1 mg/kg Rovalpituzumab tesirine 0.3 mg/kg intravenous (various dose regimens) and nivolumab intravenous (various doses and dose regimens) plus ipilimumab 1 mg/kg intravenous nivolumab plus ipilimumab 3 mg/kg Rovalpituzumab Experimental: Treatment tesirine 0.3 Arm mg/kg A: Atezolizumab Participants in Treatment Arm A will receive Atezolizumab 1,200 milligram (mg) intravenously (IV) on Day 1 of every 21-day cycle. Participants with confirmed disease progression based on RECIST 1.1 may cross over to Arm B and receive daratumumab and atezolizumab, provided crossover eligibility criteria are met. Experimental: Treatment Arm B: Atezolizumab and Daratumumab Participants will receive daratumumab 16 milligram per kilogram [mg/kg] (Safety Runin and Treatment Arm B) Intravenously (IV) weekly for 3 cycles (Day 1, 8 and 15), and Day 1 of every 21-day cycle thereafter. Atezolizumab will be administered at 1200 mg IV on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment